MX2012003050A - Co-cristales de tramadol y coxibs. - Google Patents
Co-cristales de tramadol y coxibs.Info
- Publication number
- MX2012003050A MX2012003050A MX2012003050A MX2012003050A MX2012003050A MX 2012003050 A MX2012003050 A MX 2012003050A MX 2012003050 A MX2012003050 A MX 2012003050A MX 2012003050 A MX2012003050 A MX 2012003050A MX 2012003050 A MX2012003050 A MX 2012003050A
- Authority
- MX
- Mexico
- Prior art keywords
- tramadol
- coxibs
- crystals
- crystal
- celecoxib
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a co-cristales de tramadol y formadores de co-cristal seleccionados de NSAIDs/coxibs, procesos para preparación de los mismos y sus usos como medicamentos o en formulaciones farmacéuticas, más particularmente para el tratamiento del dolor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2009/007451 WO2010043412A1 (en) | 2008-10-17 | 2009-10-16 | Co-crystals of tramadol and nsaids |
PCT/EP2010/002385 WO2011044962A1 (en) | 2009-10-16 | 2010-04-19 | Co-crystals of tramadol and coxibs |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012003050A true MX2012003050A (es) | 2012-05-29 |
Family
ID=42272447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012003050A MX2012003050A (es) | 2009-10-16 | 2010-04-19 | Co-cristales de tramadol y coxibs. |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230057884A1 (es) |
JP (1) | JP5399564B2 (es) |
KR (1) | KR101471585B1 (es) |
CN (3) | CN104817501B (es) |
AR (1) | AR079008A1 (es) |
AU (1) | AU2010306168B2 (es) |
BR (1) | BR112012005011B8 (es) |
CA (1) | CA2771665C (es) |
CO (1) | CO6511248A2 (es) |
HK (1) | HK1173380A1 (es) |
HR (1) | HRP20130316T1 (es) |
IL (1) | IL218256A (es) |
MA (1) | MA33742B1 (es) |
MX (1) | MX2012003050A (es) |
NZ (1) | NZ598353A (es) |
PT (1) | PT2488169E (es) |
SG (1) | SG178835A1 (es) |
TW (1) | TWI441630B (es) |
WO (1) | WO2011044962A1 (es) |
ZA (1) | ZA201201892B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
MX2016006464A (es) * | 2016-05-18 | 2017-11-17 | Laboratorios Liomont S A De C V | Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor. |
CN107648228A (zh) * | 2017-10-24 | 2018-02-02 | 珠海赛隆药业股份有限公司 | 一种帕瑞昔布钠与***马多组成的复合物及其用途 |
MX2018013070A (es) | 2017-12-29 | 2019-10-15 | Gruenenthal Gmbh | Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor. |
MA55954A (fr) * | 2019-05-14 | 2022-03-23 | Esteve Pharmaceuticals Sa | Utilisation de co-cristaux de tramadol et de célécoxib pour traiter la douleur tout en réduisant le risque d'abus de tramadol |
CN112007024A (zh) * | 2019-05-28 | 2020-12-01 | 江苏恒瑞医药股份有限公司 | 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661723B2 (en) * | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
WO2008085674A1 (en) * | 2007-01-04 | 2008-07-17 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions comprising celecoxib co-crystals |
US20080031950A1 (en) * | 2007-04-27 | 2008-02-07 | Nectid Inc. | Novel anelgesic combination |
-
2010
- 2010-04-19 MX MX2012003050A patent/MX2012003050A/es active IP Right Grant
- 2010-04-19 SG SG2012011672A patent/SG178835A1/en unknown
- 2010-04-19 CN CN201510128029.2A patent/CN104817501B/zh active Active
- 2010-04-19 PT PT107184723T patent/PT2488169E/pt unknown
- 2010-04-19 AU AU2010306168A patent/AU2010306168B2/en active Active
- 2010-04-19 CA CA2771665A patent/CA2771665C/en active Active
- 2010-04-19 CN CN201510128805.9A patent/CN104844513B/zh active Active
- 2010-04-19 KR KR1020127008672A patent/KR101471585B1/ko active IP Right Grant
- 2010-04-19 NZ NZ598353A patent/NZ598353A/en unknown
- 2010-04-19 JP JP2012533490A patent/JP5399564B2/ja active Active
- 2010-04-19 CN CN201080046382.1A patent/CN102573825B/zh active Active
- 2010-04-19 WO PCT/EP2010/002385 patent/WO2011044962A1/en active Application Filing
- 2010-04-19 BR BR112012005011A patent/BR112012005011B8/pt active IP Right Grant
- 2010-10-14 TW TW099135028A patent/TWI441630B/zh active
- 2010-10-15 AR ARP100103777A patent/AR079008A1/es active IP Right Grant
-
2012
- 2012-02-22 IL IL218256A patent/IL218256A/en active IP Right Grant
- 2012-03-14 ZA ZA2012/01892A patent/ZA201201892B/en unknown
- 2012-03-16 CO CO12046131A patent/CO6511248A2/es not_active Application Discontinuation
- 2012-05-11 MA MA34859A patent/MA33742B1/fr unknown
-
2013
- 2013-01-17 HK HK13100720.2A patent/HK1173380A1/ unknown
- 2013-04-09 HR HRP20130316AT patent/HRP20130316T1/hr unknown
-
2022
- 2022-10-18 US US17/968,253 patent/US20230057884A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112012005011B8 (pt) | 2021-05-25 |
JP5399564B2 (ja) | 2014-01-29 |
CA2771665C (en) | 2015-10-06 |
CN104844513A (zh) | 2015-08-19 |
JP2013507402A (ja) | 2013-03-04 |
NZ598353A (en) | 2014-01-31 |
BR112012005011B1 (pt) | 2021-01-19 |
IL218256A0 (en) | 2012-04-30 |
MA33742B1 (fr) | 2012-11-01 |
CN104844513B (zh) | 2018-08-07 |
CN102573825A (zh) | 2012-07-11 |
CO6511248A2 (es) | 2012-08-31 |
TWI441630B (zh) | 2014-06-21 |
KR20120099212A (ko) | 2012-09-07 |
HK1173380A1 (en) | 2013-05-16 |
CN104817501B (zh) | 2017-09-22 |
BR112012005011A2 (pt) | 2016-05-03 |
WO2011044962A1 (en) | 2011-04-21 |
CA2771665A1 (en) | 2011-04-21 |
AU2010306168B2 (en) | 2014-10-30 |
PT2488169E (pt) | 2013-04-03 |
AU2010306168A1 (en) | 2012-03-15 |
IL218256A (en) | 2017-05-29 |
KR101471585B1 (ko) | 2014-12-10 |
CN102573825B (zh) | 2015-04-22 |
ZA201201892B (en) | 2012-11-28 |
HRP20130316T1 (en) | 2013-05-31 |
AR079008A1 (es) | 2011-12-21 |
US20230057884A1 (en) | 2023-02-23 |
SG178835A1 (en) | 2012-05-30 |
CN104817501A (zh) | 2015-08-05 |
TW201116273A (en) | 2011-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA109534C2 (uk) | Співкристали трамадолу і коксибів | |
TN2012000515A1 (en) | Pharmaceutical compositions of co-crystals of tramadol and coxibs | |
HK1173380A1 (en) | Co-crystals of tramadol and coxibs | |
MX2015003653A (es) | Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj. | |
GB0620385D0 (en) | Novel compounds | |
IN2012DN02805A (es) | ||
MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
MX2011007774A (es) | Derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
PH12014501334A1 (en) | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines | |
MX2013008478A (es) | 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2). | |
UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
EA017091B9 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
MY156302A (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
ATE498396T1 (de) | Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes | |
WO2008043788A3 (en) | Novel compounds | |
TW200728281A (en) | Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions | |
TN2012000075A1 (en) | Co-crystals of tramadol and coxibs | |
MX2009008108A (es) | Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno. | |
CL2008001690A1 (es) | Compuestos derivados de oxazolidinonas; su procedimiento de preparacion; y sus usos para preparar un medicamento. | |
MX2012006217A (es) | Derivados de peroxido nuevos, su proceso de preparacion y su uso en medicina humana y en cosmeticos para el tratamiento o prevencion de acne. | |
WO2010027189A3 (ko) | 호모아이소플라베논 또는 이의 염의 신규한 용도 | |
TN2010000431A1 (en) | New formulations, tablets comprising such formulations, their use and process for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |